Summary

Although the guidelines for treating venous thromboembolism (VTE) in cancer patients recommend anticoagulation with low-molecular-weight heparin for at least 3 to 6 months, or for the duration of the malignancy, uncertainty exists concerning whether to extend anticoagulation longer to prevent recurrence of VTE. The objective of the Evaluation of Dalteparin for Long-Term (One Year) Treatment of Blood Clots in Subjects With Cancer study [DALTECAN; NCT00942968] was to assess the consequences of extending anticoagulation with dalteparin beyond 6 months in cancer-associated VTE.